Analyzing protein characteristics and prognosis of cervical neuroendocrine tumors
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
This study looks at the details of cervical neuroendocrine tumors in 300 patients to see how different factors might affect their treatment and survival.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Sex | Female |
| Sponsor | Fujian Maternity and Child Health Hospital Academic / other |
| Locations | 9 sites (Fuzhou, Fujian and 8 other locations) |
| Trial ID | NCT06276309 on ClinicalTrials.gov |
What this trial studies
This observational study collects clinical diagnosis and treatment data from 300 cases of cervical neuroendocrine tumors, including patient demographics, biopsy results, and survival information. Additionally, paraffin tissue specimens from 100 cases are analyzed for protein concentration and omics data to evaluate molecular characteristics and prognostic factors. The goal is to establish a follow-up database and explore the clinical application value of these findings for better understanding and treatment of cervical neuroendocrine tumors.
Who should consider this trial
Good fit: Ideal candidates are women diagnosed with cervical neuroendocrine carcinoma confirmed by histopathology.
Not a fit: Patients not treated at the participating hospitals or those lacking complete follow-up data may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the prognosis and treatment strategies for patients with cervical neuroendocrine tumors.
How similar studies have performed: While similar studies have explored molecular characteristics in other cancers, this specific approach to cervical neuroendocrine tumors is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with cervical neuroendocrine carcinoma by histopathology 2. Clinical data were complete Exclusion Criteria: 1. Patients who are not being treated in our hospital 2. Patients with lack of follow-up data, unable to obtain survival information 3. Patients call to refuse to participate in this project 4. The quality of paraffin specimens can not meet the requirements of proteome concentration determination
Where this trial is running
Fuzhou, Fujian and 8 other locations
- Fujian Maternity and Child Health Hospital — Fuzhou, Fujian, China (Recruiting)
- Fujian Provincial Hospital — Fuzhou, Fujian, China (Recruiting)
- Ningde Mindong Hospital — Ningde, Fujian, China (Recruiting)
- Putian City first Hospital — Putian, Fujian, China (Recruiting)
- The Second Affiliated Hospital of Fujian Medical University — Quanzhou, Fujian, China (Recruiting)
- Zhangzhou affiliated Hospital of Fujian Medical University — Zhangzhou, Fujian, China (Recruiting)
- Maternal and Child Health Hospital of Hubei Province — Wuhan, Hubei, China (Recruiting)
- Xiangya Hospital, Central South University — Changsha, Hunan, China (Recruiting)
- Jiangxi maternal and Child Health Hospital — Nanchang, Jiangxi, China (Recruiting)
Study contacts
- Study coordinator: Binhua Dong
- Email: dongbinhua86@fjmu.edu.cn
- Phone: +86-0591-87558732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.